Telix Reports US$186M Q1 Revenue, Up 62% YOY
Filed with ASX · · 5 pages · English
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- FDA Approves New Prostate Cancer Imaging Agent Gozellix
- Telix Completes FAP-Targeting Theranostic Acquisition
- FDA accepts BLA and grants priority review for Zircaix
- Telix Announces Change in Reporting Currency to USD
- 2024 Full Year Results Presentation
Later from Telix Pharmaceuticals
- Telix Provides Regulatory Update on TLX101-CDx
- Telix's Illuccix PSMA-PET Imaging Agent Approved in France
- Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
- Illuccix China Phase 3 Study Completes Enrolment
- Telix at ANZSNM Annual Scientific Meeting 2025
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals